Amgen Inc. (FRA:AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 138.11B |
| Revenue (ttm) | 31.57B |
| Net Income (ttm) | 5.49B |
| Shares Out | n/a |
| EPS (ttm) | 10.12 |
| PE Ratio | 25.16 |
| Forward PE | 14.44 |
| Dividend | 8.59 (3.38%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | n/a |
| Average Volume | 480 |
| Open | 253.95 |
| Previous Close | 255.15 |
| Day's Range | 253.95 - 253.95 |
| 52-Week Range | 230.75 - 318.05 |
| Beta | n/a |
| RSI | 58.21 |
| Earnings Date | Aug 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Unpacking the Latest Options Trading Trends in Amgen
High-rolling investors have positioned themselves bearish on Amgen (NASDAQ: AMGN), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tr...
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m.
Amgen: Tariff And Drug Pricing Remain Key Uncertainties
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Amgen met main goal in late stage trial for lung cancer treatment
Amgen's Imdelltra reduces death risk by 40% in small cell lung cancer patients and extends survival by 5+ months. Read more here.
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal...
Amgen drug cuts small cell lung cancer death risk by 40%
Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data fr...
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m.
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy
Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious complication of powerful chemotherapy cancer d...
Is Amgen Stock a Buy?
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)
TROY, Mich. , May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Secu...
BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)
TROY, Mich. , May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued.
NASDAQ index trades up 2% on the day. S&P index up 1.5%
The major US stock indices are moving sharply higher in reaction to the more favorable EU tariff situation. Trump on Truth Social today posted: The US trade policy is a "page-turner" with every page (...
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Better Weight Loss Stock: Amgen or Viking Therapeutics?
US stocks tumble. Yields start to weigh on the equities
U.S. equities have reversed sharply into negative territory amid a surge in Treasury yields, following a disappointing 20-year bond auction. The Dow Jones Industrial Average is down 684 points (-1.61%...
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ETCompany ParticipantsJustin Claeys - VP, IRKave Niksefat -...
Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025 and is back with more than a dozen more trades less than two weeks after her last disclosure. Here's the latest transactions...
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m.
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...